ProAct Safety Announces Resource Page for Business Safety Strategies to Deal with COVID-19
THE WOODLANDS, Texas, June 5, 2020 /PRNewswire-PRWeb/ -- ProAct Safety, a recognized pioneer of leadership and safety excellence strategies, announces its response to the magnitude of requests for free resources on dealing with safety and the impact on businesses during the pandemic.
In addition to publishing blogs and articles twice a week or more, ProAct Safety has created a landing site where all these resources are available to businesses and individuals in one place. The topics address safety issues companies may not think to consider when trying to get back to business as usual. Shawn Galloway, CEO of ProAct Safety adds, "We know this is an unprecedented time for most business and safety leaders. We want to ensure they have the resources they need to maintain focus on the pursuit of safety excellence during this difficult time."
ABOUT PROACT SAFETY ProAct Safety is a global safety excellence consultancy. The company has completed more than 2,000 successful safety strategy, leadership, culture and Behavior-Based Safety projects in nearly every major industry worldwide. Learn more at http://www.ProActSafety.com.
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...
